How Daniel Loeb, The Real Bobby Axelrod, Made His Wall Street Billions

When Damian Lewis, the actor who plays the ruthless hedge fund boss in the drama series Billions was looking for inspiration, he sat down with Daniel Loeb.

Eric Johnston

How Daniel Loeb, The Real Bobby Axelrod, Made His Wall Street Billions

November 17, 2023
When Damian Lewis, the actor who plays the ruthless hedge fund boss in the drama series Billions was looking for inspiration, he sat down with Daniel Loeb.
Read Transcript

Daniel Loeb of Third Point spoke at the Sohn Hearts & Minds Investment Conference in Sydney. Picture: Bloomberg

When Damian Lewis, the actor who plays the ruthless hedge fund boss in the drama series Billions was looking for inspiration, he sat down with Daniel Loeb.

That’s the reputation of the Wall Street investor who has taken on the might of corporates from Shell, Disney and Nestle – all in the name of making a financial killing.

‍Loeb, the founder of the $US11bn ($17bn) Third Point fund, was speaking at the Sohn Hearts & Minds conference in Sydney, the investment conference that raises funds for medical research. It was less the Billions character Bobby Axelrod appearing, rather the measured financier-turned philanthropist, however the insights were just as sharp.

Damian Lewis as Bobby ‘Axe’ Axelrod in the drama series Billions. Picture: Showtime

‍Third Point famously made a windfall in betting on Greek bonds following the Eurocrisis, making big calls shorting tech in the lead-up to the dot.com crash, and buying beaten down stocks during the GFC and Covid crashes. His fund has missed much of the initial wave in AI, although it does have exposure to firms like Amazon and Microsoft.

‍One of his big moves in the past year was moving into Europe investment bank UBS after it was effectively forced by Swiss government authorities to buy out crisis-hit rival Credit Suisse in March this year. UBS effectively paid $US3bn for somewhere between $US50-70bn of assets. UBS shares initially collapsed 16 per cent on the deal, but are now more than 40 per cent from their bottom.

‍“Regardless of what haircut you used, it was a good deal,” he says.

‍Loeb is more widely known for activist pitches that target lazy companies. He seeks a seat in the boardroom or pushes companies to sell down assets. His letters to investors don’t hold back, he once referred to the CEO of the company as being the “CVD” or chief value destroyer. Other executives at times were derided as belonging to the “lucky sperm club”.

‍Loeb says the approach initially was designed to leverage social pressure on the companies, particularly as when he was starting out, he didn’t have the capital to go after bigger companies.

‍“It was very effective at the time,” he says. “I would say we’re at the point now where we, our record in activism speaks for itself. I think the management teams, the CEOs, the good ones, anyway, see us as a useful sounding board that want to hear our thoughts on capital allocation, on benchmarking, and on how they can better present and communicate to the shareholders.”

‍Loeb says he is much more collaborative these days. But it does help to have a carrot and potential stick outstanding because “we are capable and willing to fight a proxy contest if necessary”.

‍After his speech, The Australian had the opportunity to ask Loeb if he believed companies were playing it too safe in a world of higher rates.

‍However, he was prepared to push back here. In general, Loeb thinks corporates are reacting well to a tougher environment after the Covid pandemic.

‍Daniel Loeb says good stock picking is investing against the crowd. Picture: Getty Images/AFP

‍“You’re seeing more companies focused on sustainable capital. I don’t mean environmental sustainability, but financially cutting costs, reducing debt, making sure that they don’t run into trouble. I wouldn’t say that there’s a lazy tendency in this environment.”

‍Like chasing Greek debt or unloved stocks, Loeb says one of the hallmarks of a good stock idea is betting against the crowd.

‍“Unlike something like AI, where you just say ‘wow, that’s amazing. Where do I sign up?’ I (like) an idea that you kind of go, ‘Yeah, I don’t want to be anywhere near that’.”

‍Loeb’s portfolio is now being built around opportunities in credit. In a higher interest rate environment, corporate bonds are being mispriced. So too are opportunities are arising in how companies are dealing with debt.

‍“There’s a massive amount of deleveraging. Every company that we own and follow is aggressively paying down debt with free cash flow, or opting for debt pay downs, rather than share repurchases,” Loeb says.

FULL COVERAGE: 2023 Sohn Hearts & Minds Investment Leaders Conference

Some companies that comfortably ran with medium levels of debt for years are now being punished for this and are trying to aggressively pay down debt.

‍“The opportunities won’t come from defaults as much as they will come from companies that maybe had a little bit of a hiccup at the same time that they have a need for restructuring, they’re going to need fresh capital to come in, or their existing credit to rollover into a new line.”

‍Loeb’s stock pick is something less glamorous. A small underperforming US beauty retailer Bath & Body Works that Loeb pressured and ultimately took a seat on the board. It sells beauty lotions and scented products and is moving into haircare. It has millions of customers going into their stores every month and has a new management team. He describes it as a hidden jewel with earnings potential.

‍“It is a good example of an unpopular levered smaller cap that is just throwing off a ton of cash and will be in a position to buy back a lot of equity by next year,” Loeb says.

Big themes

As glimpse of where market themes are going, this year’s Sohn Hearts & Minds conference had a distinct flavour. Leading stock pickers from a string of local and offshore managers from the Future Fund, IFM Investors, Ellerston Capital, Tribeca Investment to Bridgewater detailed their pitches. Investment picks were mostly international, with Australian-US listed medical play Resmed or ASX-listed uranium group Nexgen Energy the only local heroes amid a dozen or so tips. Other picks put value over growth in a high inflation market with stocks being under-appreciated by investors as the ones likely to deliver more potential upside.

‍The biggest shift was out of equities and into cash and other assets.

‍Tech investor Cathie Wood-backed cryptocurrency tracker, the Grayscale Bitcoin Investment Trust. Tellingly, one of Australia’s biggest investors, the $200bn Future Fund, has looked past equities and into private credit – effectively cash. The Future Fund’s chief investment officer Ben Samild says diversifying is the single best move that investors can make right now. Likewise, Bridgewater’s Atul Lele says there are better returns outside of equities in a highly inflationary environment.

‍The Hearts & Minds event has a serious side. It has established itself as a day of speed dating for markets nerds, all built with charity at the core. Since the launch of Hearts and Minds by Matthew Grounds, Guy Fowler and Gary Weiss in 2016 the event has so far raised more than $60m that has been channelled to Australian medical research. Next year, the show goes on the road to Adelaide.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Daniel Loeb of Third Point spoke at the Sohn Hearts & Minds Investment Conference in Sydney. Picture: Bloomberg

When Damian Lewis, the actor who plays the ruthless hedge fund boss in the drama series Billions was looking for inspiration, he sat down with Daniel Loeb.

That’s the reputation of the Wall Street investor who has taken on the might of corporates from Shell, Disney and Nestle – all in the name of making a financial killing.

‍Loeb, the founder of the $US11bn ($17bn) Third Point fund, was speaking at the Sohn Hearts & Minds conference in Sydney, the investment conference that raises funds for medical research. It was less the Billions character Bobby Axelrod appearing, rather the measured financier-turned philanthropist, however the insights were just as sharp.

Damian Lewis as Bobby ‘Axe’ Axelrod in the drama series Billions. Picture: Showtime

‍Third Point famously made a windfall in betting on Greek bonds following the Eurocrisis, making big calls shorting tech in the lead-up to the dot.com crash, and buying beaten down stocks during the GFC and Covid crashes. His fund has missed much of the initial wave in AI, although it does have exposure to firms like Amazon and Microsoft.

‍One of his big moves in the past year was moving into Europe investment bank UBS after it was effectively forced by Swiss government authorities to buy out crisis-hit rival Credit Suisse in March this year. UBS effectively paid $US3bn for somewhere between $US50-70bn of assets. UBS shares initially collapsed 16 per cent on the deal, but are now more than 40 per cent from their bottom.

‍“Regardless of what haircut you used, it was a good deal,” he says.

‍Loeb is more widely known for activist pitches that target lazy companies. He seeks a seat in the boardroom or pushes companies to sell down assets. His letters to investors don’t hold back, he once referred to the CEO of the company as being the “CVD” or chief value destroyer. Other executives at times were derided as belonging to the “lucky sperm club”.

‍Loeb says the approach initially was designed to leverage social pressure on the companies, particularly as when he was starting out, he didn’t have the capital to go after bigger companies.

‍“It was very effective at the time,” he says. “I would say we’re at the point now where we, our record in activism speaks for itself. I think the management teams, the CEOs, the good ones, anyway, see us as a useful sounding board that want to hear our thoughts on capital allocation, on benchmarking, and on how they can better present and communicate to the shareholders.”

‍Loeb says he is much more collaborative these days. But it does help to have a carrot and potential stick outstanding because “we are capable and willing to fight a proxy contest if necessary”.

‍After his speech, The Australian had the opportunity to ask Loeb if he believed companies were playing it too safe in a world of higher rates.

‍However, he was prepared to push back here. In general, Loeb thinks corporates are reacting well to a tougher environment after the Covid pandemic.

‍Daniel Loeb says good stock picking is investing against the crowd. Picture: Getty Images/AFP

‍“You’re seeing more companies focused on sustainable capital. I don’t mean environmental sustainability, but financially cutting costs, reducing debt, making sure that they don’t run into trouble. I wouldn’t say that there’s a lazy tendency in this environment.”

‍Like chasing Greek debt or unloved stocks, Loeb says one of the hallmarks of a good stock idea is betting against the crowd.

‍“Unlike something like AI, where you just say ‘wow, that’s amazing. Where do I sign up?’ I (like) an idea that you kind of go, ‘Yeah, I don’t want to be anywhere near that’.”

‍Loeb’s portfolio is now being built around opportunities in credit. In a higher interest rate environment, corporate bonds are being mispriced. So too are opportunities are arising in how companies are dealing with debt.

‍“There’s a massive amount of deleveraging. Every company that we own and follow is aggressively paying down debt with free cash flow, or opting for debt pay downs, rather than share repurchases,” Loeb says.

FULL COVERAGE: 2023 Sohn Hearts & Minds Investment Leaders Conference

Some companies that comfortably ran with medium levels of debt for years are now being punished for this and are trying to aggressively pay down debt.

‍“The opportunities won’t come from defaults as much as they will come from companies that maybe had a little bit of a hiccup at the same time that they have a need for restructuring, they’re going to need fresh capital to come in, or their existing credit to rollover into a new line.”

‍Loeb’s stock pick is something less glamorous. A small underperforming US beauty retailer Bath & Body Works that Loeb pressured and ultimately took a seat on the board. It sells beauty lotions and scented products and is moving into haircare. It has millions of customers going into their stores every month and has a new management team. He describes it as a hidden jewel with earnings potential.

‍“It is a good example of an unpopular levered smaller cap that is just throwing off a ton of cash and will be in a position to buy back a lot of equity by next year,” Loeb says.

Big themes

As glimpse of where market themes are going, this year’s Sohn Hearts & Minds conference had a distinct flavour. Leading stock pickers from a string of local and offshore managers from the Future Fund, IFM Investors, Ellerston Capital, Tribeca Investment to Bridgewater detailed their pitches. Investment picks were mostly international, with Australian-US listed medical play Resmed or ASX-listed uranium group Nexgen Energy the only local heroes amid a dozen or so tips. Other picks put value over growth in a high inflation market with stocks being under-appreciated by investors as the ones likely to deliver more potential upside.

‍The biggest shift was out of equities and into cash and other assets.

‍Tech investor Cathie Wood-backed cryptocurrency tracker, the Grayscale Bitcoin Investment Trust. Tellingly, one of Australia’s biggest investors, the $200bn Future Fund, has looked past equities and into private credit – effectively cash. The Future Fund’s chief investment officer Ben Samild says diversifying is the single best move that investors can make right now. Likewise, Bridgewater’s Atul Lele says there are better returns outside of equities in a highly inflationary environment.

‍The Hearts & Minds event has a serious side. It has established itself as a day of speed dating for markets nerds, all built with charity at the core. Since the launch of Hearts and Minds by Matthew Grounds, Guy Fowler and Gary Weiss in 2016 the event has so far raised more than $60m that has been channelled to Australian medical research. Next year, the show goes on the road to Adelaide.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on Nov 17, 2023. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
November 10, 2022

Why this fundie is betting on luxury as recession fears mount

Bob Desmond is Head of Claremont Global and Co-Portfolio Manager. He will present at the Sohn Hearts & Minds Investment Leaders Conference in Tasmania on November 18.

Read More
November 7, 2022

This fundie couldn’t be happier with her portfolio

Joyce Meng is a presenter at this year’s Sohn Hearts & Minds Investment Leaders Conference on November 18, which takes place in Hobart and aims to raise money for medical research.

Read More
November 2, 2022

Equity Mates: Ricky Sandler, Eminence Capital

Founder, CIO and CEO of Eminence Capital Ricky Sandler talks about launching the $5.7bn asset manager, changing market structures and why he's participating in the SH&M conference.

Read More
November 1, 2022

Auscap Asset Management founder sticks to a winning formula

When Auscap Asset Management founder Tim Carleton tips a stock at the Sohn Hearts & Minds conference in Hobart, he doubts it will be a name that shocks investors.

Read More
October 31, 2022

Markets to enter ‘new phase’ with hidden risks lurking, says top stock picker Peter Cooper

One of Australia's most influential fund managers warns that investment markets have entered a “new phase” that is set to test the ­financial system.

Read More
October 31, 2022

Why Peter Cooper can’t wait for the next 30 years on markets

The veteran fund manager says the most uncertain period of his career will deliver huge opportunities – providing his firm can stick to its system.

Read More
October 30, 2022

Why this fundie is betting big on two losing companies

Speaking to the AFR before the SH&M conference, Sandler named global on-demand ride-sharing and food delivery service Uber Technologies among his top picks, alongside real estate marketplace Zillow.

Read More
October 27, 2022

Why this fundie is calling the peak for CBA shares

Jun Bei Liu is the lead Portfolio Manager at Tribeca Alpha Plus Fund and is set to present an investment idea at the Sohn Hearts & Minds Conference in Hobart on November 18.

Read More
October 24, 2022

‘Forget forecasts – focus on quality’, says Claremont Global chief Bob Desmond

Bob Desmond is making his first appearance at the 2022 Sohn Hearts & Minds Conference.

Read More
October 24, 2022

Regal hedge fund manager says resources stocks are still cheap

Regal’s hedge fund focused on the resources space has thumped the market and its top stock picker, Tim Elliott, says resources stocks are still cheap.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.